Summary
Pfizer Inc.'s third-quarter and nine-month results for 2013 demonstrate a company navigating patent expirations and strategic divestitures while pursuing new growth areas. While overall revenues saw a slight decline year-over-year, driven by the loss of exclusivity for key products like Lipitor and ongoing collaboration expirations, the company reported a significant increase in income from continuing operations for the nine-month period. This improvement was largely due to substantial patent litigation settlement income and reduced legal charges, alongside favorable business development activities, including a significant gain on the Zoetis divestiture. Key financial shifts include a notable decrease in R&D expenses and selling, informational, and administrative costs, reflecting ongoing cost-reduction initiatives. The company's balance sheet shows a strong liquidity position, with substantial cash and short-term investments, despite increased share repurchases and dividend payments. Investors should note the substantial restructuring and acquisition-related costs impacting reported figures, and consider the company's adjusted income metrics for a clearer view of operational performance. Pfizer continues to manage its portfolio through strategic business development, focusing on key therapeutic areas and emerging markets.
Financial Highlights
53 data points| Revenue | $12.64B |
| Cost of Revenue | $2.29B |
| Gross Profit | $10.36B |
| SG&A Expenses | $3.40B |
| Operating Income | $8.75B |
| Interest Expense | $340.00M |
| Net Income | $2.59B |
| EPS (Basic) | $0.39 |
| EPS (Diluted) | $0.39 |
| Shares Outstanding (Basic) | 6.58B |
| Shares Outstanding (Diluted) | 6.66B |
Key Highlights
- 1Revenues for the third quarter of 2013 were $12.6 billion, a 2% decrease compared to the prior year, with a 7% decrease in revenues for the nine-month period to $38.0 billion.
- 2Income from continuing operations increased by 16% for the nine months ended September 29, 2013, reaching $8.8 billion, driven by patent litigation settlements and divestitures.
- 3The company completed the full disposition of its Animal Health business (Zoetis) in June 2013, resulting in a significant gain on disposal of $10.4 billion.
- 4Research and Development (R&D) expenses decreased by 14% in the third quarter and 11% in the nine-month period, reflecting cost optimization and program discontinuations.
- 5Selling, Informational, and Administrative (SI&A) expenses also decreased by 3% in the third quarter and 6% in the nine-month period, attributed to field force reductions and cost-saving initiatives.
- 6Cash provided by operating activities remained strong at $12.0 billion for the first nine months of 2013.
- 7Pfizer repurchased approximately $11.6 billion of its common stock in the first nine months of 2013, a significant increase from the prior year's $4.8 billion.